Selling pressure pushes Abbott Laboratories stock lower in today's trading

Traders Union
All News
Financial News
Abbott laboratories slides 2.29% today

Highlights

Institutional investors, including Horizon Investments and CENTRAL TRUST, significantly reduced positions in Abbott Laboratories amid broad selling pressure.
Abbott's nearly 3% dividend yield, its highest in a decade, and growing medical diagnostics business maintained its 'Dividend King' status.
Stock trades below major moving averages with strong bearish momentum, likely remaining between $84.59 and $89.31 over the next week.

Dividend yield peaks as investor outflows accelerate

Recent institutional activity saw Horizon Investments LLC reduce its holdings in Abbott Laboratories by 45.2% in the fourth quarter, while CENTRAL TRUST Co decreased its position by 10.2%. The company's dividend yield has reached nearly 3%, its highest level in a decade, and business expansion in the medical diagnostic sector was reported. Abbott Laboratories maintained its designation as a 'Dividend King' with continued business growth, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views Abbott Laboratories as deep in a technical downtrend, with price action far below critical moving averages and no nearby support. He notes that the sharply reduced positions by major institutional holders signal a lack of confidence in the stock’s near-term prospects. Despite a historically high dividend yield and its 'Dividend King' status, the fundamental picture is overshadowed by intense selling pressure and oversold technical signals. Momentum indicators remain firmly negative, showing little sign of reversal. "The persistent weakness in both fundamentals and price action keeps me defensive, as significant downside risk cannot be ignored in this setup."

Viktoras Karapetjanc, expert at Traders Union, recognizes recent reductions in major investor exposure but highlights Abbott Laboratories' ongoing business growth and elite dividend record. He sees the near-3% dividend yield as a sign of opportunity amid the current pullback. Karapetjanc believes expansion in medical diagnostics supports long-term upside, even as short-term price action remains pressured. "Market volatility offers attractive entry points, and I expect the company's solid fundamentals will foster sustained recovery going forward."

Parshwa Turakhiya, analyst, focuses on short-term oversold conditions and heightened intraday volatility for Abbott Laboratories. He notes that deep technical oversold signals, such as an RSI below 30 and a negative Bull/Bear Power, could draw tactical buyers aiming for a rebound play. However, with all four key indicators showing weakness, momentum still favors the bears and the stock remains vulnerable. "I see a possible short-lived relief rally, but ultimately caution is warranted until clear confirmation of reversal appears."

Bearish momentum persists as technical support levels give way

Abbott Laboratories is trading well below its 20-day ($96.43), 50-day ($104.06), and 200-day ($120.55) moving averages, confirming persistent pressure from sellers across short-, medium-, and long-term trends. The nearest dynamic resistance is the Ichimoku Kijun at $97.60, with no significant support above the current price.

Momentum signals are strongly bearish, as both the MACD and Average Directional Index (ADX) indicate clear downside pressure. The Relative Strength Index (RSI) at 27.56, Stochastic RSI near 30, and Commodity Channel Index (CCI) at -107 all point to oversold conditions, suggesting the stock is deeply sold off. Bull/Bear Power (BBP) is negative at -2.63, confirming sellers dominate intraday momentum and reinforcing the oversold bias. Backed by a daily drop of $2.05 (2.29% lower), the session opened with a downside gap and the price is near the session lows. Intraday volatility stands at 2.15%. This combination indicates firm selling pressure after the open, with intraday and daily momentum confirming the bearish tone.

Earlier, analysts noted that Abbott Laboratories was experiencing persistent downside pressure and a strongly bearish outlook across major technical indicators. The latest institutional selling and lack of buy signals reinforce the current downtrend, making a potential break below $84.59 the key risk investors should monitor in the near term.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.